While driving down an East Texas country road I spotted this scene. The autumn trees and the late afternoon sun made these golden bales of hay shine just a little bit more. Fortunately I had my camera with me. (c) James Q. Eddy Jr.

The Four States NPR News Source 2025 Kansas Association of Broadcasters Award Winner 2nd Place for Website in a Medium Market

Donate

Play Live Radio

Next Up:

0:00

0:00 0:00

Available On Air Stations

Stream and Listen To KRPS's Weekday Morning & Afternoon Newscasts In The NPR App

Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

NPR | By Sydney Lupkin,

Steve Inskeep

Published May 22, 2026 at 3:44 AM CDT

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

Sydney Lupkin

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

Steve Inskeep

Steve Inskeep is a host of NPR's Morning Edition, as well as NPR's morning news podcast Up First.